-
HA380 hemoperfusion cartridge-- Essential treatmen...2023-02-20 -
Golden Bull Award! Jafron Wins Golden Bull Award ...2023-02-08 -
Expert Consensus on Artificial Liver Therapy2023-02-02 -
Hemodialysis concentrate obtained registration cer...2023-01-17 -
Jafron Biomedical Announces Joining of Dr. Carolin...2023-01-17 -
Jafron won the "8th Patent Gold Award" o...2023-01-17 -
Jafron Biomedical Receives Health Canada Authoriza...2023-01-17 -
Jafron Biomedical Announces Global Advisory Board2023-01-17 -
A Product Launch Co-organized by Jafron and Nipro ...2023-01-17
-
HA380 hemoperfusion cartridge-- Essential treatments for critical illness2023-02-20
-
Golden Bull Award! Jafron Wins Golden Bull Award for Highest Investment Value o...2023-02-08
-
Expert Consensus on Artificial Liver Therapy2023-02-02
-
Hemodialysis concentrate obtained registration certificate in China2023-01-17
-
Jafron Biomedical Announces Joining of Dr. Caroline Jin as Vice President to Exp...2023-01-17
-
Jafron won the "8th Patent Gold Award" of Guangdong，China2023-01-17
-
Jafron Biomedical Receives Health Canada Authorization of its Disposable Hemoper...2023-01-17
-
Jafron Biomedical Announces Global Advisory Board2023-01-17
-
A Product Launch Co-organized by Jafron and Nipro Ecuador Branch—A Cooperation t...2023-01-17
Jafron Biomedical Co., Ltd.
Dirección: No. 98 Technology Six Road, High-tech Zone, Zhuhai City, China
Correo electrónico: customerservice@jafron.com
Sitio web: https://es.jafroninternational.com
Términos de uso｜Mapa del sitio｜ Aviso de cookies｜ Aviso de privacidad
Aviso de privacidad de la contratación
Línea directa disponible 24 horas al día, 7 días a la semana
© 2016 Jafron Biomedical Co., Ltd. Todos los derechos reservados.
